Press Release Details

Gosselies, Belgium – February 10, 2017 – iTeos Therapeutics SA, a Belgian privately-held biotechnology company applying its expertise in translational tumor immunology to the development of novel cancer immunotherapies, today announced that Michel Detheux, iTeos’ Chief Executive Officer, will present at the 2017 BIO CEO & Investor Conference on Tuesday, February 14 2017 at 10:45 a.m. ET in Park North at The Waldorf Astoria in New York, NY.

If you would like to meet with the iTeos management team, please contact the event organizers or info@iteostherapeutics.com.

For more information about the 2017 BIO CEO & Investor Conference, please refer to the conference website at: http://ceo.bio.org.

About iTeos Therapeutics S.A.

Based in Gosselies, Belgium, iTeos, a spin-off of Ludwig Cancer Research (LICR) and de Duve Institute (UCL), is focused on expanding the benefits of immunotherapy for cancer patients. The company is developing a proprietary pipeline targeting A_2A, immune checkpoints and non-immunogenic tumors.  It has licensed its IDO1 program, now in Phase 1 development, to Pfizer. iTeos’ competitive edge is in the combination of expertise in drug discovery and translational tumor immunology. The company uses a unique platform to identify rational combinations of immunotherapies and novel targets. The company is supported in part by the Walloon Region of Belgium and the FEDER (European Fund for Economic and Regional Development). For more information please visit www.iteostherapeutics.com.

Contacts:

Michel Detheux, CEO

iTeos therapeutics

+32 71 919 933

michel.detheux@iteostherapeutics.com

Sarah McCabe

Stern Investor Relations, Inc.

+ 1 212 362-1200

sarah@sternir.com

Jonathan Birt, Mathew Neal, Hendrik Thys

Consilium Strategic Communications

+44 203 709 5700

iteos@consilium-comms.com